Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update [Yahoo! Finance]
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
Antibiotic Collaboration and Licensing Deals Analysis Report 2024 with Directory of 133 Agreements Signed Since 2019 [Yahoo! Finance]